SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
23527/30 cc notes as i have been superseded by technology, here is the transcript software salesperson17/30/2009
2351finance.yahoo.com I find it of interest that INCY is leveraging clinical trialsBiotech Jim-7/30/2009
2350>Which basically seems to be a lay-up based on their Phase II results.< Wformer_pgs-7/21/2009
2349Fully agree Peter, as long as the investigators heed the trial's entrance crBiotech Jim-7/21/2009
2348<i>primary endpoint is equal to or greater than 35% reduction in spleen siBiomaven-7/21/2009
2347Very good news, apparently. I have a tiny position, unfortunately.tom pope-7/21/2009
2346This is good news, primary endpoint is equal to or greater than 35% reduction inBiotech Jim-7/21/2009
2345thanks!scaram(o)uche-6/12/2009
2344OT- <The alternate reality> From where I am sitting, I am starting to seekenhott-6/12/2009
2343Link to PFE’s webcast tomorrow at EULAR (1pm ET): visualwebcaster.comDewDiligence_on_SI-6/11/2009
2342Pfizer's Oral JAK-3 Inhibitor Demonstrates Statistically Significant Responsscaram(o)uche-6/11/2009
2341Yeah. Thanks, Sales, as always! Rickscaram(o)uche-6/11/2009
2340Rick, <I> Am I confused, or did they eventually get what they wanted, firsoftware salesperson-6/11/2009
2339>> Step one was the myelofibrosis SPA agreement which looks like a layup. scaram(o)uche-6/10/2009
2338Well..... can't do this without looking at the data and confirming that tscaram(o)uche-6/10/2009
2337<i>The alternate reality to this is that certain indications are just too DewDiligence_on_SI-6/10/2009
2336I generally agree with your comments, but would like to add two thoughts: 1) Alformer_pgs-6/10/2009
2335From Reuters last evening on their JAK3 inhibitor (I did not attend the talk, buBiotech Jim-6/10/2009
2334I am just talking of course. But to look at the diabetes market one has to decokenhott-6/9/2009
2333>>I am not sure the INCY drug stands out in a crowd. To me it does stand Biomaven-6/9/2009
2332>I think it won't be easy partnering this drug.< Depends what you askformer_pgs-6/9/2009
2331<Bottom line though is that I suspect everyone is going to want to see very lkenhott-6/9/2009
2330Incyte strategy to dig out of their hole. Step one was the myelofibrosis SPA agrrkrw-6/9/2009
2329Here's the FDA's take on metabolic syndrome (from their guidance on weigBiomaven-6/8/2009
2328One would have to have a dialogue with the agency to help create the treatment pBiotech Jim-6/8/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News